BARD1 and cancer: As pathogenic BRCA1 variants located in the RING domain disrupt BARD1-BRCA1 interaction, it was hypothesized that variants in BARD1 may also affect this interaction, thereby making BARD1 an attractive candidate to pursue in BRCA1 mutation negative cancer families.